Human Albumin Grifols

Human Albumin Grifols is a human serum albumin solution for intravenous administration, supplied as a sterile liquid preparation. It contains purified human serum albumin derived from pooled plasma and is marketed in the European Union as a volume expander. The product restores plasma oncotic pressure, supports intravascular volume, and helps manage conditions linked to low albumin levels. It is classified as a plasma protein and is given under medical supervision.

Human Albumin Grifols is indicated for clinical situations where plasma volume expansion or albumin replacement is required, particularly in critically ill or peri‑operative patients.

- Treatment of hypovolemia due to fluid loss, trauma, or surgery. - Management of circulatory shock when rapid intravascular volume support is needed. - Adjunct therapy for extensive burns to replace protein loss and maintain oncotic pressure. - Correction of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition. - Support during cardiac or vascular surgery to improve hemodynamic stability. - Therapeutic support in severe sepsis or septic shock when hypoalbuminemia contributes to vascular leakage.

Adverse reactions to Human Albumin Grifols are generally infrequent but may occur shortly after the start of infusion or later during therapy.

Common: - Transient fever, chills, or rigors occurring shortly after the start of infusion. - Mild headache or nausea that usually resolves without intervention. - Localized urticaria, pruritus, or erythema at the infusion site. - Slight fluctuations in blood pressure, presenting as either a brief rise or mild hypotension.

Serious: - Anaphylactic or severe allergic reactions, which may include bronchospasm, angioedema, or hypotensive shock. - Volume overload leading to pulmonary edema, particularly in patients with pre‑existing cardiac or renal impairment. - Hemolytic or thrombotic complications such as deep‑vein thrombosis or disseminated intravascular coagulation.

Before using Human Albumin Grifols, clinicians should evaluate patient history and clinical status to minimize risk.

- Assess cardiac function and avoid use in uncontrolled heart failure or severe left‑ventricular dysfunction. - Evaluate renal function and monitor fluid balance to prevent overload in renal insufficiency. - Verify absence of known hypersensitivity to human albumin or any plasma‑derived product before infusion. - Use caution in individuals with IgA deficiency, as they may develop anti‑IgA antibodies that can trigger reactions. - Monitor hemodynamic status during and after infusion, especially in patients after major surgery or trauma. - Adjust dosage or discontinue therapy if signs of pulmonary edema, hypertension, or severe allergic response appear.

Human Albumin Grifols may interact with certain medications or solutions, requiring attention to avoid incompatibility or altered therapeutic effect.

Avoid: - Do not mix with calcium‑ or phosphate‑containing solutions, as precipitation may occur. - Avoid simultaneous infusion with high‑dose loop diuretics that can cause rapid intravascular volume shifts. - Concurrent administration with drugs that are highly albumin‑bound (e.g., warfarin, phenytoin) may alter free‑drug concentrations.

Use with caution: - Use cautiously with anticoagulants, as changes in plasma protein binding can affect anticoagulant activity. - Monitor patients receiving vasopressors, because albumin infusion may potentiate pressor effects. - In individuals with pre‑existing hypervolemia or heart failure, closely track fluid balance to prevent overload.